

Patent case: G.D. Searle v. Sandoz B.V., Netherlands

Kluwer Patent Blog
April 9, 2019

Bart van Wezenbeek (V.O. Patents & Trademarks)

Please refer to this post as: *Bart van Wezenbeek, 'Patent case: G.D. Searle v. Sandoz B.V., Netherlands', Kluwer Patent Blog, April 9 2019, <http://patentblog.kluweriplaw.com/2019/04/09/patent-case-g-d-searle-v-sandoz-b-v-netherlands/>*

The Court concluded that the compound darunavir was not protected by a patent within the sense of Art. 3 of the SPC directive because, following the CJEU decision in *Teva v. Gilead*, it is necessary that the compound for which the SPC is granted can be specifically identified in the patent.

Case date: 08 January 2019

Case number: C/09/56199 / KG ZA 18-1112

Court: Provisions Judge of the District Court of The Hague

A full summary of this case has been published on [Kluwer IP Law](#).